2020 was a good year for cell and gene therapy (CGT) manufacturers. Financial investment in CGT companies skyrocketed by 200% and the researchers behind CRISPR/ Cas9 brought home...
Unaddressed issues can introduce risk to the manufacturing process and can cause longer startup cycles, more rejected product and increased machine malfunctions